PolyTherics and MacroGenics Sign Collaboration Agreement
News Dec 07, 2010
PolyTherics Ltd has announced the initiation of a research collaboration with MacroGenics Inc., a leader in next-generation antibody platforms and therapeutics.
PolyTherics has a range of proprietary site-specific PEGylation technologies that can improve the duration of action of a broad range of biotherapeutics. MacroGenics’ proprietary Dual-Affinity Re-Targeting (DART™) technology is a bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. PolyTherics has already shown that its TheraPEG™ PEGylation technology can extend the half-life of antibody fragments without loss of activity in vitro.
Under the research collaboration agreement with MacroGenics, PolyTherics will apply its site-specific PEGylation technologies to an initial DART protein which will then be evaluated by MacroGenics. MacroGenics has the option to use PolyTherics’ PEGylation technologies for additional DART product candidates in the future. PolyTherics has also granted MacroGenics an option to license the PEGylation technologies to enable further development and commercialization of PEGylated DART proteins.
Dr Keith Powell, Chief Executive Officer of PolyTherics said “We are very excited about working with a leader in the bi-specific antibody fragment space. Our technologies allow for site-specific PEGylation without the need for modification of the protein. We are looking forward to a productive partnership with MacroGenics.”
Dr Scott Koenig, MacroGenics’ President and Chief Executive Officer said “PolyTherics’ unique PEGylation technology appears to be well suited to enhance the pharmacologic properties of MacroGenics’ bi-specific DART proteins, furthering our commitment to produce truly ‘best-in-class’ biotherapeutics. We look forward to collaborating with PolyTherics.”
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019